Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Tomoko Akaike und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Ipilimumab, Carcinoma, Merkel Cell, Salvage Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, the MCC Patient Gift Fund at UW, Kelsey Dickson Team Science Courage Research Award: Advancing New Therapies for Merkel Cell Carcinoma.
Abstract (Originalsprache)
Merkel cell carcinoma (MCC) incidence has risen to approximately 3,000 cases annually in the USA. Although anti-programmed cell death (ligand) 1 (PD-(L)1) agents are now the first-line treatment for advanced MCC, approximately 50% of such patients do not persistently benefit. In PD-(L)1-refractory cases, ipilimumab (anti-cytotoxic T lymphocyte antigen-4) is often added; however, the extent of the clinical benefit of this combination is controversial. We identified one prospective study, three retrospective studies, and three case reports regarding this combination in refractory MCC. The aggregate response rate from retrospective studies was 32% (13 of 41 patients) with 4 complete responses (CR) and 9 partial responses (PR). In the prospective study, the response rate was very similar at 31% (8 of 26 patients; 4 CR, 4 PR). Response durability was highly variable (range 2 to >43 months), with patients achieving CR having greater durability. Immune-related adverse events (irAEs) were ≥grade III in 29% (retrospective cohort, N=41) and 36% (prospective cohort, N=50). While these aggregate data indicate adding ipilimumab should be considered in this setting, many patients with refractory MCC are ineligible due to comorbidities/irAEs, and approximately 70% will not benefit from this regimen. There is thus a significant unmet need in PD-(L)1-refractory MCC and clinical trials in this setting should be encouraged.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
- Radiation Oncology Service, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
- Division of Radiation Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
ORCID-Profile: Tomoko Akaike, Peter H Goff, Song Y Park, Shailender Bhatia, Paul Nghiem
Förderung
- NCI NIH HHS
- the MCC Patient Gift Fund at UW
- Kelsey Dickson Team Science Courage Research Award: Advancing New Therapies for Merkel Cell Carcinoma
- the ASCO Conquer Cancer Foundation
- the National Institutes of Health/National Cancer Institute
Zitieren
APA
Akaike, T., Jabbour, A. J., Goff, P. H., Park, S. Y., Bhatia, S., & Nghiem, P. (2024). Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009396
Vancouver
Akaike T, Jabbour AJ, Goff PH, Park SY, Bhatia S, Nghiem P. Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009396
BibTeX
@article{Akaike2024,
author = {Akaike, Tomoko and Jabbour, Austin J and Goff, Peter H and Park, Song Y and Bhatia, Shailender and Nghiem, Paul},
title = {Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009396}
}
EUVIMED